Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Turkish Journal of Clinics and LaboratoryOpen Access

When location meets biology: combined risk patterns drive outcomes in primary central nervous system lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

EHEmre HafızoğluSSSerhat SekmekDBDoğan Bayram

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals prognostic factors influencing overall survival in PCNSL patients, suggesting risk-adapted strategies.

Key Points

  • Poor outcomes were observed in patients with deep brain involvement and germinal center B-cell subtype.
  • Overlapping high-risk features limited multivariate analysis, indicating complexity in determining prognostic factors.
  • The median overall survival was 13.6 months, emphasizing the aggressive nature of primary central nervous system lymphoma.
  • This analysis contributes real-world data from immunocompetent patients, underlining the need for tailored treatment approaches.

Cite This Study

Hafızoğlu et al. (2025) studied this question.

synapsesocial.com/papers/68dd91d5fe798ba2fc498fe4https://doi.org/10.18663/tjcl.1761637
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas2025 · 1 citations
  2. 2Clinical characteristics and prognosis of primary central nervous system lymphoma in China: a single-center retrospective analysis of 325 patients.2025
  3. 3Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis2025
  4. 4Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database2025
  5. 5Primary central nervous system lymphomas in three “blue books” and correlation of recently defined primary large B-cell lymphoma of immune-privileged sites: Single-center experience2025